Dexcom Clarity
Data analysis and reporting platform for glucose monitoring
Company profile
Relentless innovation from the leaders in glucose health
Company profile
Dexcom is a pioneering medical technology company that has set the standard in glucose biosensing for over 25 years. The company develops innovative continuous glucose monitoring (CGM) systems that empower people to understand what is happening in their bodies in real time, helping them better manage diabetes and overall health. Dexcom's flagship products include the Dexcom G7 and G7 15 Day CGM systems, which deliver best-in-class accuracy and send glucose readings to smartphones or receivers every five minutes, and Stelo, the first over-the-counter glucose biosensor for adults not on insulin. These technologies help users understand how food, exercise, stress, and sleep affect their glucose levels, enabling better health decisions. Dexcom's systems integrate with a growing ecosystem of connected partners including insulin pumps, insulin pens and caps, automated insulin delivery algorithms, digital health apps, and wearable devices. The company serves people with all types of diabetes as well as individuals seeking to optimize their metabolic health. With a mission to transform how people worldwide track their glucose, Dexcom partners with healthcare providers, health systems, researchers, and forward-thinking organizations to expand access to life-changing glucose sensing technology. The company is committed to sustainability, advancing healthcare equity, and maintaining direct dialogue with customers through initiatives like the Dexcom Customer Advisory Council.
Company description Dexcom official website
Mission. Dexcom empowers people to take control of health through innovative glucose biosensing technology.
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Embedded deployment with recorded integration context.
Recorded integration context: AID (Automated Insulin Delivery) Algorithms, Connected Insulin Pens and Caps, Connected Insulin Pumps, Digital Health Apps, Health Systems Data Integrations, Wearable Devices.
Company milestones
Launched Stelo as first over-the-counter CGM (2024-2025). Introduced Dexcom G7 direct-to-watch feature. Formed Customer Advisory Council in January 2026. Celebrating 25+ years in glucose biosensing technology.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Data analysis and reporting platform for glucose monitoring
Companion app for remote glucose monitoring
The world's most powerful CGM system with best-in-class accuracy
Extended 15-day wear continuous glucose monitoring system
Remote glucose monitoring and sharing platform
First over-the-counter CGM for personalized glucose insights without prescription
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
The New England journal of medicine · Oct 14, 2026
Discharge Remote Monitoring Systems for Glycemic Management After Hospital Discharge.Chronic diseases and translational medicine · Sep 1, 2026
Continuous Glucose Monitoring-Informed Basal Insulin Optimization System in Adults with Type 2 Diabetes: Initial Evaluation of Efficacy, Safety, and Impact on Patient-Reported Outcomes.Diabetes therapy : research, treatment and education of diabetes and related disorders · Aug 10, 2026
Real-time continuous glucose monitoring related to reductions in inpatient and emergency department encounters and their associated costs among non-insulin-treated people with type 2 diabetes.Journal of managed care & specialty pharmacy · Jul 21, 2026
Feasibility and benefits of continuous glucose monitoring for type 1 diabetes in Rwanda: A real-world 12-month continuation phase.Diabetic medicine : a journal of the British Diabetic Association · Jul 1, 2026
Real-world outcomes using the Tandem Mobi insulin pump with Control-IQ+ technology and Dexcom G7.Diabetic medicine : a journal of the British Diabetic Association · Jul 1, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
CGM system accuracy for glucose monitoring
Sensors lasting full 15 days
5-minute reading intervals
Personal glucose monitoring and diabetes management
Receives new glucose reading every 5 minutes, eliminating guesswork in glucose management
05 · Leadership
Leadership profiles and professional links from the current Company record.
Jake Leach
President and Chief Executive Officer
Sumi Shrishrimal, CPA, CISA
Vice President Internal Audit
Matt Dolan
Executive Vice President, Strategy, Corporate Development & Dexcom Labs
Don Abbey
Executive Vice President
Sayron Ruiz
Vice President Operations
bill Stack
Chief Technology Officer
Jereme Sylvain
EVP, Chief Financial Officer
Deniz Ünal
Chief of Staff
06 · Company updates
Recent articles published on Dexcom's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
The continuous glucose monitoring leader becomes the first company selected for an FDA digital health pilot that could reshape how AI-driven medical devices reach patients.
Policy & Regulation · Jul 28, 2026
Dexcom has announced that its Stelo continuous glucose monitor — the first OTC CGM approved by the FDA — has reached one million users, with the majority being people without diabetes who are using the device for metabolic health optimization.
Digital Health & Wearables · Apr 18, 2026
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.